Europe has world-class science but a commercialization problem
Europe's latest economic strategy begins with an uncomfortable observation.
The continent is exceptionally good at producing scientific knowledge.
Its universities conduct globally competitive research.
European laboratories contribute to breakthroughs in physics, biotechnology, advanced materials, medicine, energy and engineering.
Its researchers generate patents and new technologies.
But too often the company that turns that discovery into a global commercial platform grows somewhere else.
The European Commission now wants to change that relationship.
Rather than treating research policy, startup policy, industrial policy and capital markets as separate issues, Brussels is increasingly trying to connect them into one economic-growth strategy.
The objective is straightforward: turn more European science into European products, companies, factories, intellectual property, jobs and productivity.
That sounds obvious.
In practice, it requires solving several structural weaknesses that have frustrated European policymakers for decades.
The European Innovation Act targets the gap between discovery and market
On September 9, 2026, the European Commission proposed the European Innovation Act.
Its central argument is that Europe does not merely need more inventions.
It needs a stronger system for commercializing the inventions it already produces.
The proposal focuses particularly on two obstacles.
The first is financing intellectual property.
A technology startup may own valuable patents but still struggle to borrow money against them because banks and investors lack a standardized way to value those intangible assets.
The Commission therefore wants an EU-wide intellectual-property valuation framework, a marketplace for IP transactions and advisory services that help companies commercialize patents.
The second obstacle is public procurement.
Governments spend enormous amounts of money every year, but European procurement systems do not always make it easy for public authorities to become early customers of new technology.
The proposed legislation would create a more harmonized framework for research and development procurement and make it easier for authorities in several EU countries to buy innovative technologies together.
The broader idea is important.
A scientific discovery becomes economically valuable only when somebody can finance it, manufacture it, buy it and scale it.
Commission modelling says the reforms could add hundreds of billions of euros to GDP
The European Commission's Joint Research Centre modeled the potential economic effects of three parts of the Innovation Act.
Its estimates are large.
Under a more conservative scenario, the reforms could generate almost €256 billion in additional cumulative EU GDP over ten years and support about 238,000 additional jobs at peak impact.
Under the more optimistic scenario, cumulative GDP gains could approach €452 billion, with roughly 507,000 additional jobs at peak.
These are economic-model estimates rather than guaranteed outcomes.
They depend on assumptions about whether companies actually gain access to more finance, whether governments use innovation procurement effectively and whether the wider economy responds as modeled.
But they illustrate what policymakers increasingly believe: regulatory structure can matter almost as much as direct subsidies.
Removing a barrier that prevents thousands of companies from commercializing inventions can generate economic effects across many industries simultaneously.
Intellectual property could become a financing asset
The proposed IP reforms could have a particularly large effect on young technology companies.
European startups frequently hold much more value in patents, software and scientific know-how than in physical assets.
Traditional bank lending is poorly suited to that structure.
A manufacturing company can pledge machinery or real estate as collateral.
A biotechnology startup may primarily own patents covering a molecule that has not yet reached market.
A quantum company may own algorithms and hardware designs rather than factories.
The Joint Research Centre estimates that the Innovation Act's IP measures could generate between €2.7 billion and €10.2 billion of additional IP-backed financing annually.
That would not solve Europe's venture-capital problem by itself.
But it could create another financing channel between laboratory research and large-scale commercialization.
Europe also wants governments to become better technology customers
Public procurement is one of Europe's least discussed industrial-policy tools.
European public authorities already spend billions purchasing healthcare systems, transport infrastructure, defence technologies, digital services, energy equipment and other products.
If even part of that spending is directed toward innovative technologies, governments can provide something startups need almost as much as capital: early customers.
The Commission says EU public authorities currently conduct approximately €17.3 billion of R&D procurement annually.
JRC analysis used evidence suggesting that each euro spent through R&D procurement can generate roughly three euros in supplier returns through technological learning, improved production processes and commercialization effects.
The Innovation Act therefore attempts to make procurement part of the innovation system rather than merely an administrative purchasing process.
Europe's problem appears after the startup stage
Europe does create startups.
The more difficult problem begins when successful companies need to become much larger.
Recent European Central Bank research shows that annual company birth rates in Europe and the United States are broadly similar, at around 10%.
The divergence emerges later.
European companies face greater difficulty raising the large financing rounds required to become global technology leaders.
The ECB estimates that venture-capital funds located in the United States have approximately €930 billion in total fund size.
The equivalent figure for EU funds is roughly €150 billion.
That means the U.S. VC pool is around six times larger.
The difference becomes particularly severe in late-stage rounds where a deep-tech company may require €100 million, €300 million or more before reaching profitability.
Europe can invent a company and still lose much of its economic value
When a European startup cannot find sufficiently large financing at home, several things can happen.
It can accept a U.S. investor as lead shareholder.
It can move headquarters.
It can list on a foreign stock exchange.
It can sell to a larger foreign company.
Or it can move future investment closer to the capital markets supplying its growth.
Foreign investment itself is not inherently a problem.
International capital can provide expertise, customers and funding that helps European companies become stronger.
The policy concern is what happens when Europe consistently finances the expensive scientific phase of innovation but captures too little of the later commercial value.
Public money may help create the technology while production, headquarters, capital-market activity and high-value employment eventually accumulate somewhere else.
The €5 billion Scaleup Europe Fund directly targets that problem
The Scaleup Europe Fund is one of the EU's most concrete responses.
The new fund is targeting approximately €5 billion of public and private capital for strategic European technology companies.
The European Commission is contributing €1 billion, while private and institutional investors are expected to provide additional capital.
EQT was selected to manage the vehicle independently on commercial terms.
The targeted sectors include artificial intelligence, quantum technology, semiconductors, robotics, autonomous systems, energy technology, space, biotechnology, medical technology, advanced materials and agritech.
Unlike many traditional EU innovation grants, the Scaleup Europe Fund is designed to participate in major late-stage financing rounds.
Its direct investments can reach approximately €100 million and above, including follow-on investments.
That is the stage where Europe's capital shortage becomes most visible.
Public money is being used to attract much larger pools of private money
The structure reflects a change in European industrial policy.
The EU does not intend to finance every technology champion directly from government budgets.
Instead, public capital is increasingly being used to absorb some risk or anchor investment vehicles that attract pension funds, insurers, private-equity groups and other institutional investors.
That matters because the scale of capital required by modern technology has increased dramatically.
A frontier semiconductor facility can cost tens of billions of euros.
An AI company may need billions in computing infrastructure.
A biotechnology company can spend years and enormous sums before one medicine reaches market.
Battery plants, quantum hardware, fusion systems and space infrastructure are similarly capital intensive.
Government grants alone cannot support that scale indefinitely.
Europe therefore needs deeper private capital markets alongside public research funding.
Europe's venture-capital structure itself is part of the productivity problem
The ECB argues that Europe's smaller and more fragmented venture-capital industry has broader economic consequences.
Large companies generally produce more value added per employee than micro-enterprises because they can invest more heavily in technology, specialized management, intangible assets and international expansion.
An ECB analysis published in September estimates that roughly one-third of the aggregate EU-U.S. productivity gap could be associated with differences in firm-size composition.
That does not mean making every company enormous would eliminate Europe's productivity problem.
It shows that Europe's inability to scale successful businesses can become an economy-wide issue.
A company that remains at 50 employees instead of reaching 5,000 employees does not simply remain smaller.
It may invest less in R&D, export less, train fewer specialists and create fewer supplier ecosystems.
Scale itself can become a source of productivity.
Research spending is still lower than in several competing economies
Commercialization is not Europe's only weakness.
The EU also invests a smaller share of its economy in research and development than several major competitors.
The European Commission's 2026 macroeconomic analysis puts EU R&D expenditure at approximately 2.1% of GDP in 2023.
That compares with about 3.6% in the United States, 2.6% in China, 3.4% in Japan and approximately 5% in South Korea.
The EU has long maintained an objective of reaching 3% of GDP in combined research and development expenditure.
The target remains unmet.
Closing that gap requires private-sector investment as well as government spending because businesses account for a large share of R&D in innovation-intensive economies.
The next EU budget proposal dramatically increases research and competitiveness funding
The European Commission's proposed 2028–2034 budget attempts to address the issue at much greater scale.
It proposes approximately €451 billion for competitiveness and research.
Within that framework, Horizon Europe would receive €175 billion, approximately twice the size of the current programme according to the Commission's proposal.
The proposed European Competitiveness Fund would operate alongside Horizon Europe and support strategic technologies across four broad areas: clean transition and industrial decarbonization; digital technologies; health, biotechnology, agriculture and bioeconomy; and defence and space.
The Commission says digital investment under the new budget architecture would increase roughly fivefold, while support for clean technology, bioeconomy and decarbonization would rise around sixfold.
These figures remain proposals for the 2028–2034 EU budget rather than fully deployed spending.
They still require the EU's political budget process.
Europe wants one financing chain from laboratory to global company
One of the most important ideas behind the new funding architecture is continuity.
Historically, a researcher could receive a scientific grant.
A startup could later receive an innovation grant.
A company then had to search separately for growth capital, industrial financing and commercial customers.
Each transition created another opportunity for the project to fail or move elsewhere.
The Commission says Horizon Europe and the Competitiveness Fund should increasingly support the complete investment journey from scientific conception through commercial scale-up.
That means basic research, proof of concept, startup formation, industrial demonstration, growth capital and production become parts of the same economic strategy.
The policy objective is effectively to create a European pipeline from discovery to industry.
The European Innovation Council already provides more than €1.4 billion in 2026
The European Innovation Council is another part of that pipeline.
Its 2026 work programme provides more than €1.4 billion across several schemes.
EIC Pathfinder supports high-risk scientific research capable of creating major technological breakthroughs.
EIC Transition helps turn research results into commercial opportunities.
EIC Accelerator combines grants and investment for startups and SMEs.
STEP Scale Up provides larger investments intended to catalyse funding rounds of €50 million to €150 million or more.
The Scaleup Europe Fund then extends that logic further toward companies requiring approximately €100 million or more of growth capital.
The result is an increasingly deliberate ladder of financing.
AI is making Europe's commercialization problem more urgent
Artificial intelligence has intensified the debate because technology cycles are moving much faster.
A scientific breakthrough that takes a decade to commercialize may arrive too late in a market where competitors deploy products in months.
The IMF told EU finance ministers in September that AI could raise European productivity by around 1% over five years, while also increasing economic inequality, pressure on electricity systems and dependence on foreign technology if Europe fails to build sufficient domestic capability.
European Central Bank President Christine Lagarde has separately warned that reliance on foreign AI infrastructure creates strategic vulnerabilities.
Europe is therefore trying to do two things simultaneously.
It wants companies to adopt global AI technology rapidly enough to gain productivity.
It also wants enough domestic models, chips, cloud infrastructure and technology companies that the region does not become entirely dependent on U.S. or Asian suppliers.
Europe is already strong in several technologies that could define future industries
The region is not starting from a position of technological weakness.
European institutions and companies have major capabilities in semiconductor equipment, industrial automation, aerospace, pharmaceuticals, biotechnology, quantum science, advanced manufacturing, energy technology and scientific instrumentation.
ASML is central to the global advanced-semiconductor supply chain.
European pharmaceutical groups remain major research organizations.
European universities are prominent in quantum physics and fundamental science.
Industrial companies retain considerable expertise in manufacturing and automation.
The economic challenge is converting more of those advantages into rapidly scaling businesses and new industrial ecosystems.
Biotechnology illustrates the problem clearly
European scientists make important discoveries in medicine and life sciences.
Yet pharmaceutical and biotech executives increasingly warn that clinical development and investment are shifting toward the United States and China.
In September, major European drugmakers said Europe's share of global pharmaceutical R&D had fallen from approximately 43% in 1990 to 31%, while its share of clinical trials had fallen substantially over the previous decade.
The companies called for faster trials, stronger intellectual-property protection and greater investment.
The example mirrors Europe's broader innovation dilemma.
Excellent science is not sufficient if the regulatory, financing and market environment makes commercial development more attractive elsewhere.
The single market is not yet a single startup market
Europe theoretically gives a company access to hundreds of millions of consumers.
In practice, scaling across the continent can still mean navigating different company laws, tax systems, employment rules, investment structures and administrative requirements.
A startup expanding from France into Germany, Italy and Poland may encounter substantially more complexity than a U.S. startup expanding from California into Texas and New York.
That fragmentation increases cost precisely when startups need to grow rapidly.
The ECB has therefore argued that deeper company-law and capital-market integration could help European firms scale across borders.
The debate around an EU-wide corporate regime often referred to as 'EU Inc.' reflects the same concern.
Europe's scientific market is international.
Its commercial structure is still partly national.
Regulation can protect citizens and still create an innovation cost
Europe's regulatory model is another part of the debate.
The EU has often been willing to regulate new technologies earlier than other large economies.
Supporters argue that common rules create trust, safety and legal certainty.
Critics argue that complex regulation can create high fixed compliance costs that disproportionately affect young companies.
The Commission is now trying to make those objectives less contradictory.
Alongside the Innovation Act, it proposed common principles for regulatory sandboxes.
A sandbox allows companies to test new products under regulatory supervision before every legal question has been fully resolved.
The goal is to let regulators learn from the technology while companies learn how rules will apply.
The deeper strategy is innovation-led productivity
Europe's growth challenge is not simply cyclical.
Its working-age population is aging.
Energy can be expensive.
Public debt limits how much governments can permanently stimulate demand.
That makes productivity increasingly important for long-term living standards.
If each worker can produce more value through technology, automation, better infrastructure and improved business organization, economies can grow even when labor-force growth slows.
This explains why research policy has moved from the margins of European economic policy toward its center.
AI, biotechnology, robotics and advanced manufacturing are increasingly being treated not as individual technology industries but as potential productivity infrastructure for the whole economy.
Europe does not need every startup to remain European at any cost
There is a danger in turning innovation policy into economic nationalism.
Foreign investors can strengthen European companies.
International acquisitions can reward founders and investors.
Global research collaboration is essential for science.
And protectionist policies can raise costs or reduce competition.
The more defensible European goal is not to prevent companies from using foreign capital.
It is to ensure that European firms have a credible choice to remain and expand in Europe.
If a company moves because the U.S. market offers better commercial opportunities, that is a business decision.
If it moves because Europe simply cannot supply a €300 million financing round, that represents a market-structure problem policymakers can potentially address.
Public investment alone cannot manufacture global technology companies
The scale of the new European programmes is substantial, but money cannot guarantee innovation.
Governments can finance laboratories.
They can subsidize factories.
They can invest in venture funds.
They can simplify procurement.
They cannot know in advance which startup will become the next global platform.
Excessively political capital allocation could protect weak companies or direct investment toward fashionable technologies without commercial demand.
That is one reason the Scaleup Europe Fund has been structured with an independent professional fund manager making investment decisions on market terms.
Europe's challenge is to correct financing gaps without replacing competitive markets with government selection of winners.
The €452 billion estimate should be read as a scenario, not a forecast
The headline GDP number attached to the Innovation Act is impressive.
But it needs careful interpretation.
The Joint Research Centre did not say Europe will definitely become €452 billion richer because the legislation exists.
Its analysis modeled scenarios under different assumptions about financing, procurement and economic spillovers.
The lower estimate is also substantial, at almost €256 billion cumulatively over ten years.
Real outcomes could be weaker if implementation is slow, member states apply the rules inconsistently or companies fail to respond as expected.
They could also differ because economic conditions, technology and investment markets will change over the decade.
The value of the study is less the exact number than the mechanism it highlights: removing commercialization barriers can have economy-wide effects.
Europe is effectively trying to build an innovation flywheel
The ideal system works in a cycle.
Universities create research.
Researchers create intellectual property.
Startups commercialize that IP.
Venture investors finance the companies.
Public and private customers buy the products.
Successful companies scale across Europe.
Employees gain expertise.
Founders and investors generate capital.
That capital returns to the next generation of companies.
Large companies invest more in R&D.
The resulting research starts another cycle.
Europe already has many of the individual pieces.
Its problem has been making them reinforce one another at sufficient scale.
The next phase of European economic policy is therefore about conversion
Europe does not simply want more scientific papers.
It wants more scientific papers converted into patents.
More patents converted into companies.
More companies converted into global scaleups.
More scaleups converted into industrial investment.
And more industrial investment converted into productivity and wages.
That is the logic connecting the European Innovation Act, Horizon Europe, the European Innovation Council, the Scaleup Europe Fund and the proposed European Competitiveness Fund.
Each instrument addresses a different stage of the same economic chain.
The competition is increasingly between innovation systems
The United States benefits from deep capital markets, large technology companies, world-leading universities and a large integrated domestic market.
China combines enormous industrial capacity with government-supported technology investment and a large internal market.
South Korea and Japan maintain high research intensity and specialized industrial strengths.
Europe's response is unlikely to succeed by copying any one of those systems exactly.
Its competitive advantage comes from combining scientific capability, a large single market, industrial expertise, strong institutions and large pools of household savings.
The weakness is that those assets remain insufficiently connected.
Capital does not move across borders easily enough.
Startups do not scale quickly enough.
Research does not reach customers quickly enough.
And fragmented regulation can slow deployment.
Europe's new bet is that science can become an economic-growth engine again
The policy shift now underway is larger than one innovation law or one investment fund.
European policymakers increasingly see science and technology as central to the continent's future economic model.
An aging society needs higher productivity.
Strategic competition requires stronger technology capabilities.
The energy transition requires new industrial systems.
Artificial intelligence is changing how services and manufacturing operate.
Biotechnology is becoming economically important across healthcare, agriculture and materials.
Quantum, robotics and advanced computing could create entirely new industries.
Europe already finances much of the research behind these fields.
The question is whether it can capture more of what happens next.
If the new policies succeed, the continent could turn more discoveries into companies, more companies into global industries and more technology investment into productivity growth.
If they fail, Europe risks continuing a familiar pattern: helping invent the future while watching a disproportionate share of its commercial value scale somewhere else.
That is why Europe's science policy is increasingly becoming economic policy.
Reader questions
Frequently asked questions
What is the European Innovation Act?
It is a European Commission proposal introduced in September 2026 to help scientific discoveries and innovative technologies move more easily from research into financing, commercialization and large-scale deployment across the EU.
Why does Europe need a new innovation strategy?
Europe produces strong research but often struggles to scale technology companies and commercialize discoveries. Policymakers want to close financing, regulatory and market barriers that cause economic value to move elsewhere.
How much economic growth could the European Innovation Act create?
Joint Research Centre modelling estimates roughly €256 billion to €452 billion in cumulative additional EU GDP over ten years depending on implementation assumptions. These figures are scenarios, not guaranteed forecasts.
How many jobs could the European Innovation Act create?
The JRC models approximately 238,000 additional jobs at peak under its more conservative scenario and about 507,000 under its higher-impact scenario.
How will Europe help startups finance patents?
The Innovation Act proposes a common EU framework for valuing intellectual property, an IP marketplace and advisory services that could make patents easier to use as financing assets.
How much additional IP financing could the new rules unlock?
The JRC estimates approximately €2.7 billion to €10.2 billion in additional IP-backed financing annually depending on implementation and market response.
What is the Scaleup Europe Fund?
It is a new public-private growth fund targeting approximately €5 billion for major investments in European strategic-technology companies at the scale-up stage.
How much is the EU contributing to the Scaleup Europe Fund?
The European Commission has committed approximately €1 billion, with additional capital expected from institutional and private investors.
Which technologies will the Scaleup Europe Fund target?
Target areas include artificial intelligence, quantum technology, semiconductors, robotics, autonomous systems, clean and secure energy, space, biotechnology, medical technology, advanced materials and agritech.
Why do European startups struggle to become large companies?
Major barriers include fragmented markets, smaller late-stage venture-capital pools, regulatory complexity, limited cross-border financing and difficulty obtaining very large growth rounds.
How large is Europe's venture-capital gap with the United States?
ECB analysis estimates venture funds located in the United States have roughly €930 billion in total fund size compared with around €150 billion in the EU.
How much does Europe spend on research and development?
EU R&D expenditure was approximately 2.1% of GDP in 2023 according to the Commission's 2026 macroeconomic analysis.
How does EU R&D spending compare with the United States?
The Commission places U.S. R&D spending at approximately 3.6% of GDP compared with around 2.1% in the EU for the referenced period.
What is Horizon Europe?
Horizon Europe is the EU's principal research and innovation funding programme. The Commission proposes a €175 billion budget for the 2028–2034 version.
How much does the EU propose to spend on competitiveness and research after 2027?
The Commission's proposed 2028–2034 long-term budget includes approximately €451 billion for competitiveness and research.
Is the €451 billion already approved spending?
No. It forms part of the proposed 2028–2034 EU budget framework and remains subject to the EU budget approval process.
Why is public procurement important for innovation?
Governments can become early customers for new technologies. Predictable demand can help innovative companies commercialize products, improve production and attract additional private investment.
Is Europe trying to prevent foreign investment in its startups?
The main objective is not to eliminate foreign capital but to ensure European technology companies can obtain enough financing to remain and scale in Europe if they choose.
Can government funding solve Europe's technology gap?
Not by itself. Europe also needs deeper private capital markets, faster commercialization, integrated markets, skilled workers, competitive energy and companies capable of scaling globally.
Why is science investment becoming central to European economic policy?
Europe faces slow demographic growth and productivity challenges. Policymakers increasingly see AI, biotechnology, advanced manufacturing and other technologies as tools for raising productivity, creating new industries and supporting future living standards.
Nexuswild welcomes factual corrections. Email [email protected] with evidence and the article URL.
